WASHINGTON — Former President Trump is backing off his support for a controversial drug pricing plan that struck fear into the hearts of pharmaceutical executives during his first term.
Trump in 2020 signed an executive order to make sure that Medicare didn’t pay more for prescription drugs than other developed countries. The aggressive policy could have slashed more than $10 billion per year from the pharmaceutical industry’s bottom line. The Biden administration ultimately rescinded the policy following a court order that stopped the program from going into effect.
In June 2023, Trump’s campaign released a video and statement indicating that the policy could make a comeback during a second Trump term, and said that, “On Day One, President Trump will sign an Executive Order to end global freeloading on American consumers once and for all.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in